

CITATION REPORT

List of articles citing

Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients

DOI: 10.1007/s11239-018-1738-7

Journal of Thrombosis and Thrombolysis, 2018, 46, 521-527.

Source: <https://exaly.com/paper-pdf/70943929/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
16	Clinical Management of Pharmacokinetic Drug Interactions with Direct Oral Anticoagulants (DOACs). <i>Drugs</i> , 2019 , 79, 1625-1634	12.1	12
15	Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. <i>Journal of Thrombosis and Thrombolysis</i> , 2020 , 49, 294-303	5.1	14
14	Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: A systematic review. <i>Thrombosis Research</i> , 2020 , 194, 240-245	8.2	14
13	Uninterrupted direct oral anticoagulant treatment during acute illness: Impact on clinical outcomes. <i>Thrombosis Research</i> , 2020 , 196, 457-462	8.2	1
12	Real-World Analysis of Potential Pharmacokinetic and Pharmacodynamic Drug Interactions with Apixaban in Patients with Non-Valvular Atrial Fibrillation. <i>International Journal of General Medicine</i> , 2020 , 13, 419-427	2.3	2
11	Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice. <i>Drugs</i> , 2020 , 80, 1065-1083	12.1	13
10	Effect of Enzyme-Inducing Antiseizure Medications on the Risk of Sub-Therapeutic Concentrations of Direct Oral Anticoagulants: A Retrospective Cohort Study. <i>CNS Drugs</i> , 2021 , 35, 305-316	6.7	3
9	Evaluation of Anti-Xa Apixaban and Rivaroxaban Levels With Respect to Known Doses in Relation to Major Bleeding Events. <i>Journal of Pharmacy Practice</i> , 2021 , 8971900211009075	1.3	2
8	Comparison of potential pharmacokinetic drug interactions in patients with atrial fibrillation and changing from warfarin to non-vitamin K oral anticoagulant therapy. <i>Journal of Thrombosis and Thrombolysis</i> , 2021 , 52, 1110-1116	5.1	1
7	Major bleeding events in octagenarians associated with drug interactions between dabigatran and P-gp inhibitors. <i>Journal of Geriatric Cardiology</i> , 2019 , 16, 806-811	1.7	5
6	Outcomes of Direct Oral Anticoagulants Co-Prescribed with Common Interacting Medications. <i>American Journal of Cardiology</i> , 2021 ,	3	0
5	Impact of the Genotype and Phenotype of CYP3A and P-gp on the Apixaban and Rivaroxaban Exposure in a Real-World Setting.. <i>Journal of Personalized Medicine</i> , 2022 , 12,	3.6	1
4	Simvastatin, but Not Atorvastatin, Is Associated with Higher Peak Rivaroxaban Serum Levels and Bleeding: an Asian Cohort Study from Singapore.. <i>Cardiovascular Drugs and Therapy</i> , 2022 ,	3.9	1
3	Do Apixaban Plasma Levels Relate to Bleeding? The Clinical Outcomes and Predictive Factors for Bleeding in Patients with Non-Valvular Atrial Fibrillation. 2022 , 10, 2001		0
2	Impact of amiodarone on plasma concentration of direct oral anticoagulant in patients with atrial fibrillation. 2023 ,		0
1	Clinical characteristics of patients with direct oral anticoagulant (DOAC) levels outside expected ranges: A retrospective chart study. 2023 , 100139		0